Plasma apelin levels in subjects with nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 59, Issue 7, 2010, Pages 977-981

  Ercin, Cemal Nuri ^a   Dogru, Teoman ^a   Tapan, Serkan ^a   Kara, Muammer ^a   Haymana, Cem ^a   Karadurmus, Nuri ^a   Karslioglu, Yildirim ^a   Acikel, Cengizhan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER BIOPSY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; FATTY LIVER; HUMANS; INSULIN; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MALE;

EID: 77952794694     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.10.019     Document Type: Article

References (24)

1. Polyzos S.A., Kountouras J., and Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 9 (2009) 299-314
2. Vuppalanchi R., and Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49 (2009) 306-317
3. Rayalam S., Della-Fera M.A., Krieg P.A., et al. A putative role for apelin in the etiology of obesity. Biochem Biophys Res Commun 368 (2008) 815-819
4. Bełtowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?. Med Sci Monit 12 (2006) 112-119
5. Tasci I., Dogru T., Naharci I., et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 115 (2007) 428-432
6. Erdem G., Dogru T., Tasci I., et al. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116 (2008) 289-292
7. Lago F., Dieguez C., Gómez-Reino J., et al. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 18 (2007) 313-325
8. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
9. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
10. Bonora E., Targher G., Alberiche M., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 (2000) 57-63
11. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
12. Boucher J., Masri B., Daviaud D., et al. Apelin, a newly identified adipokine upregulated by insulin and obesity. Endocrinology 146 (2005) 1764-1771
13. Daviaud D., Boucher J., Gesta S., et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 20 (2006) 1528-1530
14. Principe A., Melgar-Lesmes P., Fernández-Varo G., et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 48 (2008) 1193-1201
15. Oh D.K., Ciaraldi T., and Henry R.R. Adiponectin in health and disease. Diabetes Obes Metab 9 (2007) 282-289
16. Targher G., Bertolini L., Scala L., et al. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol. (Oxf) 61 (2004) 700-703
17. Hui J.M., Hodge A., Farrell G.C., et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004) 46-54
18. Bugianesi E., Pagotto U., Manini R., et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90 (2005) 3498-3504
19. Pagano C., Soardo G., Esposito W., et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152 (2005) 113-118
20. Shimizu A., Takamura T., Matsuzawa N., et al. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. Metab Clin Exp 56 (2007) 1478-1485
21. Nannipieri M., Cecchetti F., Anselmino M., et al. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg 19 (2009) 467-474
22. Nakayama H., Otabe S., Yuan X., et al. Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice. Metab Clin Exp 58 (2009) 901-908
23. Dogru T., Sonmez A., Tasci I., et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76 (2007) 24-29
24. Tasci I., Erdem G., Ozgur G., et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 204 (2009) 222-228